Ningbo Newbay Medical Technology describes new PARP-1 inhibitors for cancer

Nov. 24, 2023

Ningbo Newbay Medical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Nov. 4, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 4, 2024.

Regulatory actions for Oct. 31, 2024

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...

Nanocube’s nanorobots to revolutionize cancer diagnosis, treatment

BioWorld MedTech

Nanocube Health Ltd. is developing accessible, low-cost nanorobots that could revolutionize diagnosis and treatment of hard-to-diagnose cancers, with pancreatic...

Cureverse, Angelini ink $360M deal for oral Alzheimer’s drug

BioWorld

Cureverse Inc. and Angelini Pharma SpA signed a potential $360 million deal for CV-01, an oral small-molecule candidate for Alzheimer’s disease and neurological...